πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 635 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10494382

Crystalline solvate comprising 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-n

Theravance Biopharma R&D IP, LLC Β· Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10493077

Fused imidazo-piperidine JAK inhibitor compound

Theravance Biopharma R&D IP, LLC Β· Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10485803

Pyrimidine compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10472335

Crystalline(2S,4R)-5-(5β€²-chloro-2β€²-fluoro-[1,1β€²-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydro

Theravance Biopharma R&D IP, LLC Β· Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10472366

Glucuronide prodrugs of tofacitinib

Theravance Biopharma R&D IP, LLC Β· Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10441579

4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

Theravance Biopharma R&D IP, LLC Β· Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10435428

Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory diseas

Theravance Biopharma R&D IP, LLC Β· Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10426766

Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

Theravance Biopharma R&D IP, LLC Β· Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10406148

Methods of treatment using a JAK inhibitor compound

Theravance Biopharma R&D IP, LLC Β· Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10392386

JAK inhibitors containing a 4-membered heterocyclic amide

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10392368

Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10377751

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10369142

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10358433

Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist

Theravance Respiratory Company, LLC Β· Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10343995

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10336773

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10315984

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10308646

Pyrimidine compound as JAK kinase inhibitor

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10251874

Crystalline forms of a JAK inhibitor compound

Theravance Biopharma R&D IP, LLC Β· Granted Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10238642

Methods for treating neurogenic orthostatic hypotension

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10233174

Thiocarbamate prodrugs of tofacitinib

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10233172

Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10226454

Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10206913

4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

Theravance Biopharma R&D IP, LLC Β· Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted